Showing results (1741-1750 of 1,946) with videos related to
Sort By:
Pageof 195
Biology of Reproduction|November 17, 2006
Premature chromosome condensation is not essential for nuclear reprogramming in bovine somatic cell nuclear transferLi-Ying Sung, Perng-Chih Shen, B-Seon Jeong, et al.Advanced Therapeutics|December 13, 2021
Erratum: Drug Repurposing for the Treatment of COVID-19: A Knowledge Graph ApproachVincent K C Yan, Xiaodong Li, Xuxiao Ye, et al.Molecular Cancer Therapeutics|October 6, 2011
Identification of a natural compound by cell-based screening that enhances interferon regulatory factor-1 activity and causes tumor suppressionJinbo Gao, Yujun Wang, Quanhua Xing, et al.Theriogenology|April 10, 2013
Synergistic effect of trichostatin A and scriptaid on the development of cloned rabbit embryosC H Chen, F Du, J Xu, et al.Cancer Cell|October 19, 2013
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastomaQi-Wen Fan, Christine K Cheng, W Clay Gustafson, et al.Journal of Neuro-Oncology|February 18, 2015
Outcomes of gamma knife radiosurgery, bi-modality & tri-modality treatment regimens for patients with one or multiple brain metastases: the Columbia University Medical Center experienceTony J C Wang, Shumaila Saad, Yasir H Qureshi, et al.Cancer|November 29, 2023
Prognosis and risk of suicide after cancer diagnosisConnor J Kinslow, Prashanth Kumar, Mark Olfson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group BDavid M Dilts, Alan B Sandler, Matthew Baker, et al.Bioorganic & Medicinal Chemistry Letters|August 11, 2000
Quinolones as gonadotropin releasing hormone (GnRH) antagonists: simultaneous optimization of the C(3)-aryl and C(6)-substituentsJ R Young, S X Huang, I Chen, et al.Lancet (London, England)|July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksPaul E Sax, Edwin DeJesus, Anthony Mills, et al.Pageof 195